Loading
KDM3B (Lysine-specific demethylase 3B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paediatric low-grade glioma. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. Demethylation of Lys residue generates formaldehyde and succinate. May have tumour suppressor activity. Location: Nucleus (UniProt). Locus 5q31.2 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"KDM3B" OR ABSTRACT:"KDM3B" OR TITLE:"lysine demethylase 3B" OR ABSTRACT:"lysine demethylase 3B" OR TITLE:"Lysine-specific demethylase 3B" OR ABSTRACT:"Lysine-specific demethylase 3B" OR TITLE:"KIAA1082" OR ABSTRACT:"KIAA1082" OR TITLE:"NET22" OR ABSTRACT:"NET22" OR TITLE:"C5orf7" OR ABSTRACT:"C5orf7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KDM3B, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/kdm3b.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/kdm3b.json. Licence CC BY-NC 4.0.